Copper intrauterine device use and HIV acquisition in women: a systematic review
- PMID: 31919240
- PMCID: PMC6978563
- DOI: 10.1136/bmjsrh-2019-200512
Copper intrauterine device use and HIV acquisition in women: a systematic review
Abstract
Objectives: To review systematically copper intrauterine device (Cu-IUD) use and HIV acquisition in women.
Methods: We searched Pubmed, Embase and the Cochrane Library between database inception and 26 June 2019 for longitudinal studies comparing incident HIV infection among women using an unspecified IUD or Cu-IUD compared with non-hormonal or no contraceptive users, or hormonal contraceptive users. We extracted information from included studies, assessed study quality, and summarised study findings.
Results: From 2494 publications identified, seven met our inclusion criteria. One randomised controlled trial (RCT), judged "informative with few limitations", found no statistically significant differences in HIV risk between users of the Cu-IUD and either intramuscular depot medroxyprogesterone acetate (DMPA-IM) or levonorgestrel implant. One observational study, deemed "informative but with important limitations", found no statistically significant difference in HIV incidence among IUD users compared with women who had tubal ligation or who were not using any contraception. Another "informative but with important limitations" observational study found no difference in HIV incidence between Cu-IUD users and DMPA or norethisterone enanthate injectable, or implant users. An RCT considered "unlikely to inform the primary question" also found no difference in HIV risk between Cu-IUD and progestogen-only injectable users. Findings from the other three "unlikely to inform the primary question" cohort studies were consistent with the more robust studies suggesting no increased risk of HIV acquisition among Cu-IUD users.
Conclusion: The collective evidence, including that from a large high-quality RCT, does not indicate an increased risk of HIV acquisition among users of Cu-IUDs.
Keywords: human immunodeficiency virus; intrauterine devices.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: TC was a member of the ECHO trial consortium. PCH, KMC, TC participated in the 2019 WHO Guideline Development Group (GDG) process which assessed recommendations on contraception for women at high risk of HIV.
Figures
Comment in
-
Contraception and HIV: an exercise in clarity.BMJ Sex Reprod Health. 2020 Jan;46(1):2-3. doi: 10.1136/bmjsrh-2019-200557. BMJ Sex Reprod Health. 2020. PMID: 31919238 No abstract available.
Similar articles
-
HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.Lancet. 2019 Jul 27;394(10195):303-313. doi: 10.1016/S0140-6736(19)31288-7. Epub 2019 Jun 13. Lancet. 2019. PMID: 31204114 Free PMC article. Clinical Trial.
-
Hormonal contraception and HIV acquisition among women: an updated systematic review.BMJ Sex Reprod Health. 2020 Jan;46(1):8-16. doi: 10.1136/bmjsrh-2019-200509. BMJ Sex Reprod Health. 2020. PMID: 31919239 Free PMC article.
-
Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.Reprod Health. 2021 Sep 29;18(1):192. doi: 10.1186/s12978-021-01232-6. Reprod Health. 2021. PMID: 34587971 Free PMC article. Clinical Trial.
-
The safety of intrauterine devices among young women: a systematic review.Contraception. 2017 Jan;95(1):17-39. doi: 10.1016/j.contraception.2016.10.006. Epub 2016 Oct 19. Contraception. 2017. PMID: 27771475 Free PMC article. Review.
-
The safety of intrauterine devices in breastfeeding women: a systematic review.Contraception. 2016 Dec;94(6):725-738. doi: 10.1016/j.contraception.2016.07.006. Epub 2016 Jul 13. Contraception. 2016. PMID: 27421765 Free PMC article. Review.
Cited by
-
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.MMWR Recomm Rep. 2024 Aug 8;73(4):1-126. doi: 10.15585/mmwr.rr7304a1. MMWR Recomm Rep. 2024. PMID: 39106314 Free PMC article.
-
Contraception and Abortion Care for People Living With HIV: A Clinical Guide for Reproductive Health Practitioners.J Midwifery Womens Health. 2023 Nov-Dec;68(6):719-727. doi: 10.1111/jmwh.13575. Epub 2023 Oct 30. J Midwifery Womens Health. 2023. PMID: 37903728 Free PMC article. Review.
-
Contraceptive effects on the cervicovaginal microbiome: Recent evidence including randomized trials.Am J Reprod Immunol. 2023 Nov;90(5):e13785. doi: 10.1111/aji.13785. Am J Reprod Immunol. 2023. PMID: 37881121 Free PMC article. Review.
-
A Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products.Open Access J Contracept. 2023 Jun 13;14:83-94. doi: 10.2147/OAJC.S375634. eCollection 2023. Open Access J Contracept. 2023. PMID: 37332341 Free PMC article. Review.
-
Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection.MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):405-410. doi: 10.15585/mmwr.mm6914a3. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32271729 Free PMC article.
References
-
- Ahmed K, Baeten JM, Beksinska M, et al. . HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet 2019;394:303–13. 10.1016/S0140-6736(19)31288-7 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
